NA-AION Risk Factors: New Perspectives
- Conditions
- Optic Disk DrusenNon-arteritic Ischemic Optic Neuropathy
- Registration Number
- NCT05305079
- Lead Sponsor
- Rigshospitalet, Denmark
- Brief Summary
The purpose of the study is to use new diagnostic methods (OCT and OCT-A) to shed light on risk factors for the development of NA-AION. The risk factors we are focusing on are comorbidities along with anatomical and vascular characteristics of the optic nerve.
- Detailed Description
Non-arteritic anterior ischemic optic neuropathy (NA-AION) is the most common acute optic neuropathy in the middle-aged and elderly population and can also occur in children and young adults. NA-AION leads to irreversible vision loss, and there is currently no effective treatment. In recent years, acellular calcified deposits in the optic nerve head called optic disc drusen (ODD) have been investigated as an important risk factor for NA-AION in patients under the age of 50.
The purpose of the study is to use new diagnostic methods optical coherence tomography (OCT) and OCT-angiography (OCTA) to shed light on risk factors for the development of NA-AION. We will perform two sub-studies:
1. Characteristics of the optic nerve head anatomy including the presence of ODD as risk factors for the development of NA-AION.
2. Vascular comorbidities and in vivo vasculature as a risk factor for developing NA-AION.
The study is an international prospective multicenter study including 20 sites in 9 different countries. The study population is patients diagnosed with NA-AION in a 1.5-year inclusion period. Each included patient gets 1-2 follow up visits during a 3-month follow up time.
Included patients will be examined as per standard clinical care for that site including OCT and OCT-A. Standard clinical care includes at least: obtaining medical history, measurement of visual acuity, slit lamp examination, and automated perimetry.
Characteristics and risk factors in NA-AION patients with ODD (ODD-AION) will be compared with NA-AOIN patients without ODD (nODD-AION).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 179
-
Diagnosis of first episode of NA-AION in study eye with symptom onset within 1 month prior
-
Subject age: Age >10
-
NA-AION diagnosis requires:
- disc edema seen by site PI or by referring doctor
- visual field defect in the study eye consistent with NA-AION and mean deviation worse than 3.0 dB using the study visual field examination protocol
- relative afferent pupillary defect (unless the fellow eye had previous NA-AION or other optic nerve or retinal disease that is not exclusionary)
- Previous episode of NA-AION in the study eye only
- Intraocular pressure of >21 mm Hg in the study eye
- Clinical or pathological evidence of giant cell arteritis
- Diseases that may affect the optic nerve: glaucoma, multiple sclerosis, Alzheimer disease, and Parkinson disease. Evidence of optic disc drusen and optic nerve hypoplasia are not exclusion criteria given they are important parts of the study. We will not exclude significant retinal diseases, since they may be related to underlying etiologies giving rise to ODD, such as macular degeneration, retinal dystrophies, but eyes with significant retinal diseases will be analyzed separately.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Anatomical characteristics on OCT 3-months follow-up visit Presence of ODD. Diameter of the scleral canal, disc area and rim on each quadrant of the optic disc, thickness of the peripapillary choroid, presence of peripapillary hyperreflective ovoid mass-like structures, and prelaminar hyperreflective lines.
Vascular characteristics on OCT-A 3-months follow-up visit Transient versus persistent findings of ischemia, segmental location and extent of reduced vessel density. If ODD is present the vessel density will be compared to ODD location and volume.
- Secondary Outcome Measures
Name Time Method Best corrected visual acuity 3-months follow-up visit Assessed on Snellen or ETDRS chart
Visual field test 3-months follow-up visit Autoperimetry: SITA fast or standard 24-2
ODD characteristics At 3-months follow-up visit If ODD is present the volume and location of the ODD (superficial vs. deep) is measured using 3D-segmentation
Questionnaire score: NEI-VFQ-25 including 10-item NO supplement score 3-months follow-up visit Score on questionnaire: National Eye Institute Visual Function Questionnaire 25 and 10-item Neuro-Ophthalmic Supplement.
A vision-targeted composite score of the NEI-VFQ-25 together with the 10-item NO supplement score is calculated. The scale is 0-100 where a high score represents better functioning.Prevalence of comorbidities At enrollment ischemic heart disease, stroke (ischemic or hemorrhagic), arterial hypertension, diabetes mellitus, end stage renal disease, smoking (now or previous), dyslipidemia, obstructive sleep apnea/continuous positive airway pressure (CPAP) use, phosphodiesterase-5 inhibitor use or ocular surgery.
Trial Locations
- Locations (20)
Farabi Eye Hospital
🇮🇷Teheran, Iran, Islamic Republic of
Sheba Medical Center
🇮🇱Tel Aviv, Israel
Capital and Coast DHB
🇳🇿Wellington, New Zealand
University of Cambridge
🇬🇧Cambridge, United Kingdom
King's College Hospital
🇬🇧London, United Kingdom
Moorfield's Eye Hospital
🇬🇧London, United Kingdom
Stanford Medicine
🇺🇸Palo Alto, California, United States
UCSF Medical Center
🇺🇸San Francisco, California, United States
University og Colorado
🇺🇸Boulder, Colorado, United States
Massachusetts Eye and Ear
🇺🇸Boston, Massachusetts, United States
John A. Moran Eye Center
🇺🇸Salt Lake City, Utah, United States
Sydney Eye Hospital
🇦🇺Sydney, Australia
University of Calgary
🇨🇦Calgary, Canada
Research St. Joseph's
🇨🇦Hamilton, Canada
Lawson Health Research Institute
🇨🇦London, Canada
Aalborg University Hospital
🇩🇰Aalborg, Denmark
Aarhus University Hospital
🇩🇰Aarhus, Denmark
Odense University Hospital
🇩🇰Odense, Denmark
Zealand University Hospital
🇩🇰Roskilde, Denmark
Bordeaux University Hospital
🇫🇷Bordeaux, France